Lung cancer Patients' own immune cells could be new weapon

NCT ID NCT06455917

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a therapy using a patient's own tumor-infiltrating lymphocytes (TILs) to treat advanced non-small cell lung cancer. Doctors collect immune cells from a tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if this slows cancer growth. The trial enrolls 30 adults who have already tried standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tumor-infiltrating lymphocytes (TILs)
What this could lead to: If successful, this could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong: This is an early phase II trial with only 30 participants, so results may not apply broadly. The treatment involves intensive chemotherapy and carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Department of Medical Oncology, University Hospital Basel
RECRUITING

Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.